These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15459209)

  • 41. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB; Goldman B; Tangen CM; Hussain M; Petrylak DP; Page S; Klein EA; Crawford ED;
    J Urol; 2007 Nov; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
    Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P
    Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.
    Wu EQ; Mulani P; Farrell MH; Sleep D
    Value Health; 2007; 10(5):408-14. PubMed ID: 17888106
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Convergent discriminitive, and predictive validity of the Prostate Cancer Specific Quality of Life Instrument (PROSQOLI) assessment and comparison with analogous scales from the EORTC QLQ-C30 and a trial-specific module. European Organisation for Research and Treatment of Cancer. Core Quality of Life Questionnaire.
    Stockler MR; Osoba D; Corey P; Goodwin PJ; Tannock IF
    J Clin Epidemiol; 1999 Jul; 52(7):653-66. PubMed ID: 10391659
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Quality of life of patients with prostatic cancer under hormonal therapy].
    Aliaev IuG; Aslamazov EG; Demidko IuL
    Urologiia; 2010; (1):46, 48-51. PubMed ID: 20891045
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan.
    Inoue T; Segawa T; Kamba T; Yoshimura K; Nakamura E; Nishiyama H; Ito N; Kamoto T; Habuchi T; Ogawa O
    Urology; 2009 May; 73(5):1104-9. PubMed ID: 19394511
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of quality of life scores in patients with oesophageal cancer.
    Blazeby JM; Brookes ST; Alderson D
    Br J Surg; 2000 Mar; 87(3):362-73. PubMed ID: 10718971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases.
    Klaff R; Berglund A; Varenhorst E; Hedlund PO; Jǿnler M; Sandblom G;
    BJU Int; 2016 Jun; 117(6):904-13. PubMed ID: 26033416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health-related quality of life in pain-free or mildly symptomatic patients with metastatic hormone-resistant prostate cancer following treatment with the specific endothelin A receptor antagonist zibotentan (ZD4054).
    Dawson N; Payne H; Battersby C; Taboada M; James N
    J Cancer Res Clin Oncol; 2011 Jan; 137(1):99-113. PubMed ID: 20390429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patient satisfaction with health-related quality of life: implications for prognosis in prostate cancer.
    Lis CG; Gupta D; Grutsch JF
    Clin Genitourin Cancer; 2008 Sep; 6(2):91-6. PubMed ID: 18824431
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors influencing health related quality of life in cancer patients with bone metastases.
    Wong E; Chow E; Zhang L; Bedard G; Lam K; Fairchild A; Vassiliou V; Alm El-Din MA; Jesus-Garcia R; Kumar A; Forges F; Tseng LM; Hou MF; Chie WC; Bottomley A
    J Palliat Med; 2013 Aug; 16(8):915-21. PubMed ID: 23819731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Health-related quality of life supersedes other psychosocial predictors of long-term survival in cancer patients undergoing radiotherapy.
    Sehlen S; Marten-Mittag B; Herschbach P; Schweden M; Book K; Henrich G; Dühmke E; Dinkel A
    Acta Oncol; 2012 Nov; 51(8):1020-8. PubMed ID: 22616951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of cumulative incidence function under the proportional hazards model.
    Cheng SC; Fine JP; Wei LJ
    Biometrics; 1998 Mar; 54(1):219-28. PubMed ID: 9544517
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hormone-resistant prostate cancer with symptomatic pelvic tumours: patient survival and prognostic factors.
    Hernes EH; Linja M; Fosså SD; Visakorpi T; Berner A; Winderen M; Koivisto PA
    BJU Int; 2000 Aug; 86(3):240-7. PubMed ID: 10930923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer.
    Eton DT; Shevrin DH; Beaumont J; Victorson D; Cella D
    Value Health; 2010 Aug; 13(5):613-23. PubMed ID: 20230544
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer.
    Sullivan PW; Nelson JB; Mulani PM; Sleep D
    Qual Life Res; 2006 Oct; 15(8):1297-306. PubMed ID: 16830258
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The management of hormone-relapsed prostate cancer.
    Parkinson RW; Austin RH; Parr NJ
    BJU Int; 2004 May; 93(7):1115. PubMed ID: 15142178
    [No Abstract]   [Full Text] [Related]  

  • 58. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036.
    Eisenberger MA; Crawford ED; Wolf M; Blumenstein B; McLeod DG; Benson R; Dorr FA; Benson M; Spaulding JT
    Semin Oncol; 1994 Oct; 21(5):613-9. PubMed ID: 7939752
    [No Abstract]   [Full Text] [Related]  

  • 59. Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.
    Ediebah DE; Quinten C; Coens C; Ringash J; Dancey J; Zikos E; Gotay C; Brundage M; Tu D; Flechtner HH; Greimel E; Reeve BB; Taphoorn M; Reijneveld J; Dirven L; Bottomley A;
    Cancer; 2018 Aug; 124(16):3409-3416. PubMed ID: 29905936
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer.
    Sullivan PW; Mulani PM; Fishman M; Sleep D
    Qual Life Res; 2007 May; 16(4):571-5. PubMed ID: 17294287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.